Market Cap 2.23B
Revenue (ttm) 6.94M
Net Income (ttm) -212.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,060.37%
Debt to Equity Ratio 0.00
Volume 1,958,300
Avg Vol 1,175,376
Day's Range N/A - N/A
Shares Out 113.25M
Stochastic %K 46%
Beta 2.11
Analysts Strong Sell
Price Target $35.23

Company Profile

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 939 7410
Address:
18702 North Creek Parkway, Suite 100, Bothell, United States
SuperGreenToday
SuperGreenToday May. 19 at 9:29 PM
$IMNM Share Price: $19.68 Contract Selected: Dec 18, 2026 $20 Calls Buy Zone: $3.65 – $4.51 Target Zone: $6.88 – $8.41 Potential Upside: 78% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Jeff9905
Jeff9905 May. 12 at 11:12 PM
$IMNM great news. Cash till 2028. Will be bought out way before for 200+. Mark this post.
0 · Reply
Doozio
Doozio May. 7 at 5:32 AM
$IMNM it’s final FORM was always ONTO 🐒🍌🧠⏰♾️
0 · Reply
RadioIsotope25
RadioIsotope25 May. 5 at 3:49 PM
Judgement day coming for $RADX soon on final phase 2b data that shocked the trading world back on Dec 15th. Active & Trending RADX & $IMNM Stocks - YouTube $INTC https://www.youtube.com/watch?v=BmpSfQi1SHg
0 · Reply
RadioIsotope25
RadioIsotope25 May. 1 at 8:29 PM
$RADX Final data out in 4 weeks! https://youtu.be/BmpSfQi1SHg $IMNM
0 · Reply
HunterT
HunterT Apr. 16 at 9:07 PM
$IMNM don’t be shocked when this gets bought out for $80 a share like seagen was
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 15 at 9:56 PM
$IMNM RSI: 67.50, MACD: 0.3523 Vol: 1.14, MA20: 21.30, MA50: 21.98 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Cycle144
Cycle144 Apr. 15 at 1:14 PM
$IMNM< 'Breakout Points to Higher Highs Ahead' -Bull pennant breakout - continuation of recovery -Strong demand confirmed by volume spike #Immunome #Bio https://www.fxempire.com/forecasts/article/immunome-imnm-price-forecast-breakout-points-to-higher-highs-ahead-1591674
1 · Reply
HunterT
HunterT Apr. 14 at 3:38 PM
$IMNM $30S please
0 · Reply
vergeband
vergeband Apr. 10 at 12:22 PM
@stockwatcherking can I ask what you think about $IMNM i work in oncology and I like their pipeline. Just getting started with investing. Said I would never do biotech again but this company is scooping up good people.
3 · Reply
Latest News on IMNM
Immunome price target lowered to $33 from $37 at Leerink

2026-05-15T10:26:52.000Z - 5 days ago

Immunome price target lowered to $33 from $37 at Leerink


Immunome reports Q1 EPS (48c), consensus (54c)

2026-05-12T22:13:25.000Z - 8 days ago

Immunome reports Q1 EPS (48c), consensus (54c)


Immunome Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 8 days ago

Immunome Earnings release: Q1 2026


Immunome Quarterly report: Q1 2026

May 12, 2026, 4:00 PM EDT - 8 days ago

Immunome Quarterly report: Q1 2026


Immunome Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 26 days ago

Immunome Proxy statement: Proxy filing


Immunome Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 26 days ago

Immunome Proxy statement: Proxy filing


Immunome Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 3:00 PM EDT - 2 months ago

Immunome Transcript: Leerink Global Healthcare Conference 2026


Immunome price target lowered to $30 from $32 at Lake Street

2026-03-05T13:43:42.000Z - 2 months ago

Immunome price target lowered to $30 from $32 at Lake Street


Immunome price target raised to $36 from $33 at Craig-Hallum

2026-03-04T14:16:41.000Z - 2 months ago

Immunome price target raised to $36 from $33 at Craig-Hallum


Immunome price target lowered to $30 from $33 at Stephens

2026-03-04T12:17:08.000Z - 2 months ago

Immunome price target lowered to $30 from $33 at Stephens


Immunome price target raised to $39 from $35 at JPMorgan

2026-03-04T11:37:36.000Z - 2 months ago

Immunome price target raised to $39 from $35 at JPMorgan


Immunome reports FY25 EPS ($2.43), consensus ($2.21)

2026-03-03T21:15:38.000Z - 2 months ago

Immunome reports FY25 EPS ($2.43), consensus ($2.21)


Immunome Annual report: Q4 2025

Mar 3, 2026, 3:00 PM EST - 2 months ago

Immunome Annual report: Q4 2025


Immunome Earnings release: Q4 2025

Mar 3, 2026, 3:00 PM EST - 2 months ago

Immunome Earnings release: Q4 2025


Immunome Slides: Corporate presentation

Mar 3, 2026, 7:00 AM EST - 2 months ago

Immunome Slides: Corporate presentation


Immunome to Present at Upcoming Investor Conferences

Feb 23, 2026, 8:00 AM EST - 3 months ago

Immunome to Present at Upcoming Investor Conferences


Immunome initiated with a Buy at H.C. Wainwright

2026-02-12T11:11:35.000Z - 3 months ago

Immunome initiated with a Buy at H.C. Wainwright


Immunome Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 1:30 PM EST - 4 months ago

Immunome Slides: 44th Annual J.P. Morgan Healthcare Conference


Immunome falls -7.2%

2025-12-17T15:06:41.000Z - 5 months ago

Immunome falls -7.2%


Immunome 18.625M share Spot Secondary priced at $21.50

2025-12-17T01:20:19.000Z - 5 months ago

Immunome 18.625M share Spot Secondary priced at $21.50


Immunome Announces Pricing of Public Offering of Common Stock

Dec 16, 2025, 8:16 PM EST - 5 months ago

Immunome Announces Pricing of Public Offering of Common Stock


Immunome price target raised to $32 from $22 at Lake Street

2025-12-16T13:46:22.000Z - 5 months ago

Immunome price target raised to $32 from $22 at Lake Street


Immunome price target raised to $40 from $18 at Evercore ISI

2025-12-16T13:11:29.000Z - 5 months ago

Immunome price target raised to $40 from $18 at Evercore ISI


Immunome price target raised to $35 from $25 at Guggenheim

2025-12-16T13:00:28.000Z - 5 months ago

Immunome price target raised to $35 from $25 at Guggenheim


Immunome offers to sell $400M in common stock

2025-12-15T21:05:38.000Z - 5 months ago

Immunome offers to sell $400M in common stock


Immunome Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 5 months ago

Immunome Announces Proposed Public Offering of Common Stock


Immunome price target raised to $40 from $38 at Leerink

2025-12-15T20:10:15.000Z - 5 months ago

Immunome price target raised to $40 from $38 at Leerink


Immunome Transcript: Study Result

Dec 15, 2025, 8:30 AM EST - 5 months ago

Immunome Transcript: Study Result


Immunome Press release: Study Result

Dec 15, 2025, 8:30 AM EST - 5 months ago

Immunome Press release: Study Result


Immunome Slides: Study Result

Dec 15, 2025, 8:30 AM EST - 5 months ago

Immunome Slides: Study Result


Immunome's experimental drug meets main goal in late-stage study

Dec 15, 2025, 7:16 AM EST - 5 months ago

Immunome's experimental drug meets main goal in late-stage study


Immunome Slides: Corporate presentation

Dec 15, 2025, 7:00 AM EST - 5 months ago

Immunome Slides: Corporate presentation


Immunome Slides: Corporate Presentation

Nov 10, 2025, 6:00 PM EST - 6 months ago

Immunome Slides: Corporate Presentation


Immunome Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 6 months ago

Immunome Earnings release: Q3 2025


Immunome Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 6 months ago

Immunome Quarterly report: Q3 2025


Infinimmune Announces Research Collaboration with Immunome

Sep 18, 2025, 8:00 AM EDT - 8 months ago

Infinimmune Announces Research Collaboration with Immunome


Immunome Slides: Corporate Presentation

Sep 8, 2025, 6:00 PM EDT - 9 months ago

Immunome Slides: Corporate Presentation


Immunome Quarterly report: Q2 2025

Aug 6, 2025, 9:30 AM EDT - 10 months ago

Immunome Quarterly report: Q2 2025


Immunome Earnings release: Q2 2025

Aug 6, 2025, 9:30 AM EDT - 10 months ago

Immunome Earnings release: Q2 2025


Immunome Slides: Investor Presentation

May 21, 2025, 10:00 AM EDT - 1 year ago

Immunome Slides: Investor Presentation


Immunome Earnings release: Q1 2025

May 12, 2025, 12:00 AM EDT - 1 year ago

Immunome Earnings release: Q1 2025


Immunome Quarterly report: Q1 2025

May 12, 2025, 12:00 AM EDT - 1 year ago

Immunome Quarterly report: Q1 2025


Immunome Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Immunome Proxy statement: Proxy Filing


Immunome Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Immunome Proxy statement: Proxy Filing


Immunome Annual report: Q4 2024

Mar 19, 2025, 4:00 PM EDT - 1 year ago

Immunome Annual report: Q4 2024


Immunome Earnings release: Q4 2024

Mar 19, 2025, 4:00 PM EDT - 1 year ago

Immunome Earnings release: Q4 2024


Immunome to Present at Upcoming March Conferences

Feb 25, 2025, 8:00 AM EST - 1 year ago

Immunome to Present at Upcoming March Conferences


Immunome Slides: FY 2025

Jan 15, 2025, 12:45 PM EST - 1 year ago

Immunome Slides: FY 2025


3 Small-Cap Stocks With Big Growth Potential

Dec 13, 2024, 7:01 AM EST - 1 year ago

3 Small-Cap Stocks With Big Growth Potential

AENT HNRG


Immunome Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Immunome Quarterly report: Q3 2024


Immunome Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Immunome Earnings release: Q3 2024


Immunome Quarterly report: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Immunome Quarterly report: Q2 2024


Immunome Earnings release: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Immunome Earnings release: Q2 2024


Immunome Appoints Phil Tsai as Chief Technical Officer

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Immunome Appoints Phil Tsai as Chief Technical Officer


Immunome Announces Completion of Purchase of Assets from Atreca

May 20, 2024, 8:00 AM EDT - 2 years ago

Immunome Announces Completion of Purchase of Assets from Atreca


Immunome Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Immunome Quarterly report: Q1 2024


Immunome Earnings release: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Immunome Earnings release: Q1 2024


Immunome Slides: Corporate Presentation

May 13, 2024, 7:00 AM EDT - 2 years ago

Immunome Slides: Corporate Presentation


Immunome Appoints Kinney Horn as Chief Business Officer

May 2, 2024, 8:00 AM EDT - 2 years ago

Immunome Appoints Kinney Horn as Chief Business Officer


Immunome Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Immunome Proxy statement: Proxy Filing


Immunome Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Immunome Proxy statement: Proxy Filing


Immunome Appoints Sandra M. Swain to Board of Directors

Apr 25, 2024, 8:26 AM EDT - 2 years ago

Immunome Appoints Sandra M. Swain to Board of Directors


Immunome Earnings release: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Immunome Earnings release: Q4 2023


Immunome Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Immunome Annual report: Q4 2023


SuperGreenToday
SuperGreenToday May. 19 at 9:29 PM
$IMNM Share Price: $19.68 Contract Selected: Dec 18, 2026 $20 Calls Buy Zone: $3.65 – $4.51 Target Zone: $6.88 – $8.41 Potential Upside: 78% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Jeff9905
Jeff9905 May. 12 at 11:12 PM
$IMNM great news. Cash till 2028. Will be bought out way before for 200+. Mark this post.
0 · Reply
Doozio
Doozio May. 7 at 5:32 AM
$IMNM it’s final FORM was always ONTO 🐒🍌🧠⏰♾️
0 · Reply
RadioIsotope25
RadioIsotope25 May. 5 at 3:49 PM
Judgement day coming for $RADX soon on final phase 2b data that shocked the trading world back on Dec 15th. Active & Trending RADX & $IMNM Stocks - YouTube $INTC https://www.youtube.com/watch?v=BmpSfQi1SHg
0 · Reply
RadioIsotope25
RadioIsotope25 May. 1 at 8:29 PM
$RADX Final data out in 4 weeks! https://youtu.be/BmpSfQi1SHg $IMNM
0 · Reply
HunterT
HunterT Apr. 16 at 9:07 PM
$IMNM don’t be shocked when this gets bought out for $80 a share like seagen was
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 15 at 9:56 PM
$IMNM RSI: 67.50, MACD: 0.3523 Vol: 1.14, MA20: 21.30, MA50: 21.98 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Cycle144
Cycle144 Apr. 15 at 1:14 PM
$IMNM< 'Breakout Points to Higher Highs Ahead' -Bull pennant breakout - continuation of recovery -Strong demand confirmed by volume spike #Immunome #Bio https://www.fxempire.com/forecasts/article/immunome-imnm-price-forecast-breakout-points-to-higher-highs-ahead-1591674
1 · Reply
HunterT
HunterT Apr. 14 at 3:38 PM
$IMNM $30S please
0 · Reply
vergeband
vergeband Apr. 10 at 12:22 PM
@stockwatcherking can I ask what you think about $IMNM i work in oncology and I like their pipeline. Just getting started with investing. Said I would never do biotech again but this company is scooping up good people.
3 · Reply
EingeLTrade
EingeLTrade Apr. 1 at 8:29 PM
Up from here❔🤔 $IMNM
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Mar. 31 at 5:21 PM
$GH $KYMR $IMNM $NAMS $SOPH OCS PVLA ZYM SRZN ^^ best of the best healthcare / biotech names right now
0 · Reply
TradeMechanics_
TradeMechanics_ Mar. 31 at 2:24 PM
Insider signal just dropped on $IMNM CEO Clay B. Siegall stepped in and bought 25,450 shares on the open market, with a weighted average price of $19.67 (range: $19.63–$19.70). That’s not a small gesture—that’s conviction buying from the top. When leadership puts real capital to work at these levels, it often signals alignment with the company’s outlook. Insiders don’t chase headlines—they buy when they believe the current price undervalues the story. Is this a bottom signal or just confidence in execution ahead? Either way, it’s a datapoint worth watching closely.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Mar. 31 at 1:15 PM
$IMNM CEO purchased 25,450 shares at $19.67 for a total of $500,602. SIEGALL CLAY B now owns 690,704 shares. https://ceo-buys.com
0 · Reply
FilingTracker
FilingTracker Mar. 31 at 11:13 AM
$IMNM $500K insider purchase by President and CEO: https://www.sec.gov/Archives/edgar/data/1167496/000116749626000003/xslF345X06/form4-03312026_110335.xml
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 28 at 1:42 PM
Radiopharm Theranostics (ASX: RAD) Investor Webinar -- RAD 101 Phase 2b second interim data - Zoom $RADX $ARTL $DRTS $IMNM https://us02web.zoom.us/rec/play/jHo4QT2d91u1IuLLzNdkfW7O01zHB8XV7X4-USlV2y-4TPZFkHt4U3BZJIlXY9cRVVMI-WgS-3Ji3Rtg.dh4n_6T8eCGOud-B
3 · Reply
RadioIsotope25
RadioIsotope25 Mar. 23 at 11:08 PM
$RADX Meets 90% news just broke on RAD101 $IMNM $AKTS
0 · Reply
Jeff9905
Jeff9905 Mar. 19 at 5:41 PM
$IMNM so they have tripled their employee count in the last 18 months. Why can't they get anything to the finish line?
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 15 at 3:23 PM
Radiopharmaceutical buyouts and Market Caps $RADX $IMNM $PYXS $CELC
1 · Reply
RadioIsotope25
RadioIsotope25 Mar. 13 at 4:43 PM
Diamond in the Rough $RADX $PYXS $IMNM $SMMT $AKTS
0 · Reply
EingeLTrade
EingeLTrade Mar. 10 at 1:56 PM
Added more $IMNM
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 6 at 12:18 AM
$30 target @ Jones Trading for Radiopharm Theranostics. $IMNM $PYXS $SLS $IOVA $RADX
3 · Reply